Document:

rare-ex101_44.htm

Exhibit 10.1

March 5, 2020

Ms. Shalini Sharp

Executive Vice President and Chief Financial Officer

Ultragenyx Pharmaceutical Inc.

60 Leveroni Court

Novato, CA 94949

 

Re: Transition

Dear Shalini:

You have announced your intention to retire from your position of Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (the “Company”) on the date that is the earlier of (i) the date your successor Chief Financial Officer of the Company commences employment and (ii) September 2, 2020 (such date, the “Officer Resignation Date”).   

This letter agreement confirms the terms and conditions for your transition that have been discussed:

	
1.
	
Transition Period and Transition Period Duties:  In consideration for your promises in this letter agreement, during the period beginning from the Officer Resignation Date until the Separation Date (as defined below) (the “Transition Period”), you shall continue to serve as an employee of the Company but will no longer have the powers, duties and responsibilities commensurate with the position of Executive Vice President and Chief Financial Officer.  During the Transition Period, your primary responsibility will be to transition your duties and institutional knowledge to the new Chief Financial Officer, and to provide assistance on or lead projects as requested by the Company’s Chief Executive Officer and/or the new Chief Financial Officer.  

 

	
2.
	
Termination of Employment: Your employment with the Company will terminate effective as of the date that is six months after the Officer Resignation Date, or such earlier date following the Officer Resignation Date that you and the Company mutually agree in writing (such date, the “Separation Date”).

 

	
3.
	
Compensation: Prior to the Transition Period, you will continue to be paid your full base salary of $501,900 per year.  During the Transition Period, you will receive a reduced base salary of $380,000, in each case payable in accordance with the Company’s normal payroll practices.  You will continue to be eligible for all regular employee benefits during the Transition Period, provided, however, that you will remain eligible for coverage under the Company’s healthcare benefit plans only if you work at least 30 hours per week.  During the Transition Period, you will be reimbursed for authorized 

www.ultragenyx.com        Transforming good science into great medicine for rare genetic diseases

                           

 

		
work-related expenses in accordance with the Company’s expense reimbursement policy.

 

	
4.
	
Bonus for 2020:  If the Company achieves the financial and other corporate goals of the Company’s bonus plan for 2020 and awards bonuses to other senior executives of the Company, you will receive your target bonus for 2020, representing 45% of your annual base salary for 2020, as long as you confirm your acceptance of the terms and conditions in this letter agreement and before or on the Separation Date, sign the transition agreement substantially in the form attached hereto as Exhibit A (the “Transition Agreement”).  The amount of the bonuses for all participants will determined based on the Company’s actual results against its financial and other corporate goals for the year.  The bonus will be paid to you in a single, lump-sum payment at the same time that bonuses for performance in 2020 are paid to other senior executives.

 

	
5.
	
Equity Awards:  You will not be entitled to any future equity award grants from the Company.  However, your outstanding equity awards consisting of options to purchase Company shares (“Options”), shares of restricted stock units (“RSUs”), and performance stock units (“PSUs”) shall continue to vest during the Transition Period.  All Options, RSUs and PSUs held by you that are unvested as of the Separation Date shall terminate and be forfeited as of such date.  In addition, as long as you confirm your acceptance of the terms in this letter agreement and you sign the Transition Agreement, all vested Options, RSUs and PSUs held by you as of the Separation Date shall remain exercisable until the date that is 120 days after the Separation Date.  

 

	
6.
	
Return of Company Property:  On or before your Separation Date, except to the extent otherwise mutually agreed between you and the Company, you will return all property of the Company that came into your possession as a result of your employment, including, but not limited to, the originals and all copies of all documents and files (whether paper or electronic), keys, company credit cards, telephones, computers, and other Company equipment. 

 

	
7.
	
Confidential Information and Trade Secrets:  You agree to fully comply with the terms of your Confidential Information and Inventions Assignment Agreement, including the terms of that agreement that remain in effect after your employment ends.   

 

	
8.
	
Release of Claims:  By signing this letter agreement, you are representing that you are not aware of any factual basis for any legal claims against the Company and that you have been paid all wages, commissions and bonuses that you believe that you are owed through the date you sign this letter agreement.  Since the benefits in this letter agreement go beyond what you are entitled to under the Company’s policies, you agree that this letter agreement constitutes a full and final settlement of any and all claims, known or unknown, of any kind that you or your dependents may have through the date you sign this letter agreement against the Company or any of its parent or affiliated companies and their officers, directors, shareholders, employees, insurers, agents, successors, or assigns (“Released Parties”), and you agree never to bring any legal action against any of the Released Parties based on any such claim, except for a claim for violation of the federal Age Discrimination in Employment Act, which is not waived in this letter agreement.  The claims released in this letter agreement include, but are not limited to, claims arising from your hiring, employment, compensation, or separation, and arising under any contract or law.

 

To ensure that your release covers all claims, known and unknown, not specifically exempted, you waive any rights you may have under any law designed to protect against 

                                                        2

 

the waiver of unknown claims, such as Section 1542 of the Civil Code of the State of California, which provides as follows: “A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.” Nothing contained in this Section 8 or any other provision of this letter agreement shall release or waive any right that you have to indemnification by the Company with respect to which you may be eligible as provided in California Labor Code section 2802, any indemnification agreement signed by you, any coverage for your benefit under the Company’s director and officer insurance policy, or any other applicable source. 

 

	
9.
	
Confidentiality:  You represent and agree that you will not hereafter disclose the facts, terms or amount of this letter agreement to anyone other than your personal advisors or tax preparers, all of whom, together with their employees and agents, if any, will be informed of and bound by the confidentiality provision.  You understand that this specifically prevents, but is not limited to, disclosures to any past or present employee, or applicant for employment, of the Company or any of its related entities.  The parties agree that the confidentiality obligations set forth in this Section 9 shall not apply to any terms or amounts set forth in this letter agreement that are otherwise made public by the Company. 

 

	
10.
	
Voluntary Agreement:  You acknowledge that you are entering into this letter agreement freely and voluntarily with a full understanding of its terms including the release of all claims.

 

	
11.
	
Complete Agreement:  You agree that this letter agreement sets forth all of the terms, promises, representations and understandings between you and the Company and that it supersedes any previous understandings or agreements, except as provided for in Section 13 below and as provided in any other agreements you have signed with the Company concerning confidential information, trade secrets or the assignment of inventions and your arbitration agreement shall remain in effect.  

 

	
12.
	
No Admission:  This letter agreement is offered and entered for the purpose of assisting you in your transition to retirement.  It is not, and you agree not to contend that it is, an admission of any wrongdoing of any kind by the Company, its employees or any of the other Released Parties.

 

	
13.
	
At-Will Employment:  If you accept this offer of retirement transition assistance, you will remain an at-will employee until the Separation Date.  Therefore, you could decide to end your employment before your Separation Date and the Company likewise could do so.  Except as expressly modified by this letter agreement, the Offer Letter between you and the Company dated March 12, 2012, as amended by Amendment No. 1 dated August 8, 2014 (as amended, the “Offer Letter”) shall remain in full force and effect in accordance with its terms until the Separation Date however, for the avoidance of doubt, neither your voluntary resignation as the Company’s Executive Vice President and Chief Financial Officer, nor the termination of your employment pursuant to Section 2 above shall give rise to any severance benefits under the Offer Letter. 

 

You should consult with your own personal attorney to the extent you desire before signing this letter agreement.  We are happy for you and appreciate your willingness to assist us during this period of transition.  

Sincerely,

                                                        3

 

 

/s/ Emil D. Kakkis, M.D., Ph.D.

Name: Emil D. Kakkis, M.D., Ph.D.

Title:  President and Chief Executive Officer

 

I voluntarily accept and agree to terms and conditions of this letter agreement.  

/s/ Shalini Sharp March 5, 2020

Shalini SharpDate

 

 

                                                        4

 

 

Exhibit A

 

Form of Transition Agreement 

                                                        5

 

CONFIDENTIAL TRANSITION AGREEMENT AND GENERAL RELEASE

This Confidential Transition Agreement and General Release (this “Agreement”) is hereby entered into by and between Shalini Sharp, an individual (the “Employee”), and Ultragenyx Pharmaceutical Inc., on behalf of itself and all of its affiliated entities (collectively, the “Company”).

1.Effective Date.  Except as otherwise provided herein, this Agreement shall be effective on the eighth calendar day after it has been executed by both of the parties (the “Effective Date”), unless the Specified Sections (as defined in Section 12(c), below) have been timely and properly revoked as provided in Section 12(c) before the Effective Date.

2.Separation from Employment.  The Employee has been employed by the Company as its Executive Vice President and Chief Financial Officer on an at-will basis pursuant to the employment offer letter between the Company and the Employee dated as of March 12, 2012, as amended by the Amendment to the offer letter dated as of August 8, 2014 (the “Employment Agreement”).  The Employee separated from her employment with the Company, effective at the close of business on _________, 202_ (the “Separation Date”).  The parties hereto agree that the Employment Agreement shall be terminated as of the Separation Date.

3.Continuation of Benefits After the Separation Date.  The Employee’s coverage under the Company’s health care benefits plans will end on the Separation Date, but the Employee shall have the right to continue her group health benefits coverage in accordance with the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1986 (“COBRA”).  Except as expressly provided in this Agreement or in the plan documents governing the Company’s employee benefit plans, after the Separation Date, the Employee will no longer be eligible for, receive, accrue, or participate in any benefits or benefit plans provided by the Company, including, without limitation, the Company’s 401(k) retirement plan; provided, however, that nothing in this Agreement shall waive the Employee’s right to any vested amounts in the Company’s 401(k) retirement plan, which amounts shall be handled as provided in the applicable plan documents.

4.Final Wages.  The Company timely paid the Employee the unpaid portion of her annual salary earned through the Separation Date and for all earned and unused vacation time by having a check for this amount available for pick-up by, or, at her option, sending it to the Employee by overnight mail or direct deposit transfer on, that date.

5.Transition Bonus Payment.  In return for the Employee’s promises in this Agreement, the Company will provide the Employee with a target bonus representing 45% of the Employee’s annual base salary of $501,900 (the “Transition Bonus Payment”), with the amount of the Transition Bonus Payment to be determined based on the Company’s actual results against the Company’s financial and other corporate goals of the Company’s bonus plan for fiscal year 2020 and provided that bonuses are awarded to other Company executives.  The Transition Bonus Payment will be paid in a single, lump-sum payment at the same time that bonuses for 2020 are paid to other executives, as long as this Agreement has become effective. 

6.Stock Options, Restricted Stock Units and Performance Stock Units. As of the date of this Agreement, the Employee holds certain options (the “Options”) to purchase Company shares, shares of restricted stock units (the “RSUs”) and performance stock units (“PSUs”).  Any Options, RSUs and PSUs that are vested as of the Separation Date will be exercisable until the date that is 120 days from the Separation Date (the 

                                                        6

 

“Expiration Date”).  Any vested Options, RSUs and PSUs not exercised by the Expiration Date will thereafter immediately terminate and be forfeited.  For the avoidance of doubt, any portion of the Employee’s Options, RSUs and PSUs that were not vested as of the Separation Date shall terminate and be forfeited as of the Separation Date. 

7.Acknowledgement of Total Compensation and Indebtedness.  The Employee acknowledges and agrees that the cash payments in Sections 4 and 5 of this Agreement extinguish any and all obligations for monies, or other compensation or benefits that the Employee claims or could claim to have earned or claims or could claim is owed to her as a result of her employment by the Company through the Separation Date, including any bonus or other incentive compensation.

8.Tax Consequences.  The Employee acknowledges that the Company has not made any representations to her about, and that she has not relied upon any statement in this Agreement with respect to, any individual tax consequences that may arise by virtue of any payment provided under this Agreement, including, but not limited to, the applicability of Section 409A of the Internal Revenue Code.

9.Releases.

(a)(i) Except as otherwise expressly provided in this Agreement, the Employee, for herself and her heirs, executors, administrators, assigns, affiliates, successors and agents (collectively, the “Employee’s Affiliates”) hereby fully and without limitation releases and forever discharges the Company, its parents, affiliates, subsidiaries, predecessors, successors and each of their respective agents, representatives, shareholders, owners, officers, directors, employees, consultants, attorneys, auditors, accountants, successors and assigns (collectively, the “Releasees”), both individually and collectively, from any and all rights, claims, demands, liabilities, actions, causes of action, damages, losses, costs, expenses and compensation, of whatever nature whatsoever, known or unknown, fixed or contingent (“Claims”), which the Employee or any of the Employee’s Affiliates has or may have or may claim to have against the Releasees by reason of any matter, cause, or thing whatsoever, under any law or contract from the beginning of time to the Effective Date.

(ii) the Company for itself and its parents, affiliates, subsidiaries and predecessors (the “Company Affiliates”) represents and agrees that as of the date this Agreement is signed it is not aware of any acts, omissions, conduct or factual basis for any Claims against Employee, and therefore, the Company on behalf of itself and the Company Affiliates further represents and agrees that it has no intention of pursing any Claim against the Employee.  Notwithstanding the foregoing, the parties agree that the representations provided for in this Section 9(a)(ii) exclude and do not apply to any Claims that are unknown as of the date this Agreement is signed. 

(b)Governmental Agencies.  Notwithstanding the release of claims language set forth in this Section 9, nothing in this Agreement prohibits or prevents Employee from filing a charge with or participating, testifying, or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state, or local government agency, nor does anything in this Agreement preclude, prohibit, or otherwise limit, in any way, Employee’s rights and abilities to contact, communicate with, report matters to, or otherwise participate in any whistleblower program administered by any such agencies.

(c)Nothing contained in this Section 9 or any other provision of this Agreement shall release or waive any right that the Employee has to indemnification by the 

                                                        7

 

Company with respect to which the Employee may be eligible as provided in California Labor Code section 2802, any indemnification agreement signed by the Employee, any coverage for the benefit of the Employee under the Company’s director and officer insurance policy, or any other applicable source.  

10.Waiver of Civil Code Section 1542. 

(a)The Employee understands and agrees that the release provided herein extends to all Claims released above whether known or unknown, suspected or unsuspected.  The Employee expressly waives and relinquishes any and all rights she may have under any law designed to prevent the waiver of unknown claims, such as California Civil Code Section 1542, which provides as follows:

“A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”

(b)It is the intention of the Employee through this Agreement to fully, finally and forever settle and release the Claims as set forth above.  In furtherance of such intention, the release herein given shall be and remain in effect as a full and complete release of such matters notwithstanding the discovery of any additional Claims or facts relating thereto.

11.Release of Federal Age Discrimination Claims by the Employee.  The Employee hereby knowingly and voluntarily waives and releases all rights and claims, known or unknown, arising under the Age Discrimination In Employment Act of 1967, as amended, which she might otherwise have had against the Company or any of the other Releasees regarding any actions which occurred prior to the Effective Date.

12.Rights Under the Older Workers Benefit Protection Act.  In accordance with the Older Workers Benefit Protection Act of 1990, the Employee hereby is advised of and acknowledges the following:

(a)The Employee has the right to consult with an attorney before signing this Agreement and is encouraged by the Company to do so;

(b)The Employee has been given twenty-one (21) calendar days after being presented with this Agreement to decide whether or not to sign this Agreement.  If the Employee signs this Agreement before the expiration of such period, the Employee does so voluntarily and after having had the opportunity to consult with an attorney; and

The Employee has seven (7) calendar days after signing this Agreement to revoke Sections 7, 9, 10 and 11 of this Agreement (collectively, the “Specified Sections”), which must be revoked in their entirety and as a group, and the Specified Sections of this Agreement (as a group) will not be effective until that revocation period has expired without exercise.  The Employee agrees that in order to exercise her right to revoke the Specified Sections of this Agreement within such seven (7) day period, she must do so in a signed writing delivered to the Company’s Vice President of Human Resources, Bee Nguyen, by email sent to: bnguyen@ultragenyx.com before the close of business on the seventh calendar day after she signs this Agreement.  If the Employee timely revokes the Specified Sections 

                                                        8

 

of this Agreement, she will not receive any portion of the Transition Bonus Payment or other benefits under this Agreement.

13.Confidentiality of Agreement.  After the execution of this Agreement by the Employee, neither the Employee, her attorney, nor any person acting by, through, under or in concert with them, shall disclose any of the terms of or amount paid under this Agreement or the negotiation thereof to any individual or entity except to the extent previously publicly disclosed by the Company; provided, however, that the foregoing shall not prevent such disclosures by the Employee to her attorney, tax advisors and/or her spouse, or as may be required by law.  The Company agrees that it will not disclose the terms of or amount paid under this Agreement to any individual or entity who does not have a legitimate business need to know; provided, however, that the foregoing shall not prevent such disclosures by the Company as may be required by law, including without limitation, pursuant to any rule or regulation by the Securities and Exchange Commission.   

14.No Filings.  The Employee warrants that as of the date of execution of this Agreement, she has not commenced, filed, participated in, offered testimony, or assisted any investigation, hearing, or proceeding (including any whistleblower proceeding) before any federal, state, or local government agency relating to the Company.  In addition, to the maximum extent permitted by law, the Employee agrees that if any lawsuits or claims, charges or complaints are made against the Company or the other Releasees with any local, state or federal agency or court in whole or in part on her behalf, the Employee shall not be entitled to recover any individual monetary relief or other individual remedies, and that, if any such agency or court ever assumes jurisdiction over any such lawsuit, claim, charge or complaint and/or any agency purports to bring any legal proceeding, in whole or in part, on behalf of the Employee based upon events occurring prior to the execution of this Agreement, the Employee will request such agency or court to withdraw from and/or to dismiss the lawsuit, claim, charge or complaint with prejudice.  The Employee further warrants that she has disclosed, or will disclose prior to the execution of this Agreement, any and all known or suspected violations of law.  Such disclosure must include how she has firsthand knowledge of the known or suspected violation.  If the Employee previously reported such known or suspected violation, such disclosure must also include who the violation was previously reported to and how such violation has not been cured.  The Employee also agrees that to the maximum extent allowed by law she will not induce, encourage, solicit or assist any other person or entity to file or pursue any proceeding of any kind against the Company or the other Releasees or voluntarily appear or invite a subpoena to testify in any such legal proceeding.  This Section 14 shall not prohibit the Employee from challenging the validity of the ADEA release in Section 11 of this Agreement.    

15.Confidential and Proprietary Information.

(a)The Employee acknowledges that during the course of or related to her employment with the Company she was provided access to certain confidential and/or proprietary information regarding the Company and its business that is not generally known outside of the Company and that would not otherwise have been provided to her (collectively, “Confidential and Proprietary Information”).  Confidential and Proprietary Information includes, without limitation, the following materials and information (whether or not reduced to writing and whether or not patentable or protected by copyright): legal strategies and advice; trade secrets; inventions; processes; formulae; programs; technical data; financial information; research and product development; marketing and advertising plans and strategies; customer identities, lists, and confidential information about customers and their buying habits; confidential information about prospects, suppliers, distributors, vendors, and key employees; personal information relating to the Company’s employees; mailing and email lists; and any other confidential, proprietary and or attorney-client 

                                                        9

 

privileged information relating to the Company or its business.   The Employee agrees that the Confidential and Proprietary Information is the sole property of the Company.  The Employee further agrees that she will not disclose to any person or use any such Confidential and Proprietary Information without the written consent of the Company’s General Counsel.  If the Employee is served with a deposition subpoena or other legal process calling for the disclosure of Confidential and Proprietary Information, or if she is contacted by any third person requesting such information, she will notify the Company’s General Counsel as soon as is reasonably practicable after receiving notice and will cooperate with the Company in preventing or minimizing the disclosure thereof.  The Employee acknowledges that certain rights and obligations set forth in the Employee’s Confidential Information and Inventions Assignment Agreement (the “Confidential Information Agreement”) extend beyond the Separation Date.  In the event that any provision of this Section 15(a) or any other provision of this Agreement conflicts with the Confidential Information Agreement, the terms and provisions of the section(s) providing the greatest protection to the Company shall control.

(b)The Employee represents and warrants that she has returned all files, customer lists, financial information, mobile devices, computers (and related passwords), and other property of the Company that were in her possession or control without retaining either electronically stored or physical copies thereof, except to the extent otherwise mutually agreed between the Employee and the Company.    

(c)Notwithstanding the confidentiality obligations set forth in this Section 15 or elsewhere in this Agreement, the Employee understands that, pursuant to the Defend Trade Secrets Act of 2016 (“DTSA”), the Employee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  The Employee further understands that if a court of law or arbitrator determines that she misappropriated Company trade secrets willfully or maliciously, including by making permitted disclosures without following the requirements of the DTSA as detailed in this Section 15(c), then the Company may be entitled to an award of exemplary damages and attorneys' fees against her.

16.Remedies.  The Employee acknowledges that any misappropriation or misuse of trade secrets or unauthorized disclosure of Confidential and Proprietary Information of the Company, and any violation of Sections 13 and 15 of this Agreement, will result in irreparable harm to the Company, and therefore, the Company shall, in addition to any other remedies, be entitled to immediate injunctive relief.  In the event of a breach of any provision of this Agreement by the Employee, including Sections 13 and 15, the Company shall, without excluding other remedies available to them, be entitled to an award in an amount equal to the Transition Bonus Payment paid to her as of the date of such breach.

17.Cooperation Clause.  The Employee agrees to cooperate with the Company’s and its legal counsel’s reasonable requests for information or assistance, including related to the Company’s finance and accounting matters, any Company internal investigation or review of compliance, legal or any other issues, response to any lawfully served civil or criminal subpoenas, and defense of, or other participation in, any administrative, judicial, or other proceeding arising from any charge, complaint or other action which has been or may be filed relating to the period during which the Employee was engaged in employment with the Company.  The Company agrees to reimburse the Employee for any reasonable expenses incurred by the Employee in connection with such 

                                                        10

 

cooperation as long as the parties have discussed and agreed upon the expense before it is incurred.   The Employee may retain independent counsel of her choice if she is personally named in any legal action related to her employment with the Company, subject to the prior written consent of the Company, which consent shall not be unreasonably withheld. Except as required by law, or authorized in advance by the Company’s General Counsel, the Employee will not communicate, directly or indirectly, with any third party, including any person or representative of any group of people or entity who is suing or has indicated that a legal action against the Company or any of its directors or officers is being contemplated, concerning the operations of the Company or the legal positions taken by the Company.  Except as required by law, if asked about any such individuals or matters, the Employee shall say: “I have no comment,” and shall direct the inquirer to the Company’s General Counsel.  The Employee acknowledges that any violation of this Section 17 will result in irreparable harm to the Company and will, in addition to other available remedies, shall be entitled to immediate injunctive relief and to an award in an amount equal to the Transition Bonus Payment paid to her as the date of such breach.

18.Non-disparagement.  Except as required by law, the Employee agrees not to disparage or otherwise publish or communicate derogatory statements about the Company and any director, officer or employee and/or the products and services of the Company to any third party.  Except as required by law, the Company agrees that its directors and officers shall not disparage or otherwise publish or communicate derogatory statements about the Employee to any third party.

19.Clawback. Notwithstanding any other provisions in this Agreement to the contrary, any amount paid to Employee pursuant to the this Agreement or any other agreement or arrangement with the Company which is subject to recovery under any law, government regulation or stock exchange listing requirement will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement).    

20.Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of California, without giving effect to principles of conflict of laws.

21.Arbitration.  The parties hereto agree that any future dispute of any nature whatsoever between them, including, but not limited to, any claims of statutory violations, contract or tort claims, or claims regarding any aspect of this Agreement, its formation, validity, interpretation, effect, performance or breach, or any act which allegedly has or would violate any provision of this Agreement (“Arbitrable Dispute”) will be submitted to arbitration in Marin County, California, unless the parties agree to another location, before an experienced employment arbitrator licensed to practice law in California and selected in accordance with the employment arbitration rules of Judicial Arbitration and Mediation Services, Inc. (“JAMS”), unless the parties agree to a different arbitrator, as the exclusive remedy for any such Arbitrable Dispute. Should any party to this Agreement hereafter institute any legal action or administrative proceeding against the other with respect to any claim waived by this Agreement or pursue any Arbitrable Dispute by any method other than said arbitration, the responding party shall be entitled to recover from the initiating party all damages, costs, expenses and attorneys’ fees incurred as a result of such action. This Section 21 shall not restrict actions for equitable relief by the Company for violation of Sections 13, 15, 17 and 18 of this Agreement. 

22.Dispute-Related Attorneys’ Fees.  Except as otherwise provided herein, in any arbitration or other proceeding between the parties arising out of or in relation 

                                                        11

 

to this Agreement, including any purported breach of this Agreement, the prevailing party shall be entitled to an award of its costs and expenses, including reasonable attorneys’ fees.

23.Non-Admission of Liability.  The parties understand and agree that neither the payment of any sum of money nor the execution of this Agreement by the parties will constitute or be construed as an admission of any wrongdoing or liability whatsoever by any party.

24.Severability.  If any one or more of the provisions contained herein (or parts thereof), or the application thereof in any circumstances, is held invalid, illegal or unenforceable in any respect for any reason, the validity and enforceability of any such provision in every other respect and of the remaining provisions hereof will not be in any way impaired or affected, it being intended that all of the rights and privileges shall be enforceable to the fullest extent permitted by law.

25.Entire Agreement.  This Agreement represents the sole and entire agreement among the parties, and, except as expressly stated herein, supersedes all prior agreements, negotiations and discussions among the parties with respect to the subject matters contained herein, including the Employment Agreement. 

26.Waiver.  No waiver by any party hereto at any time of any breach of, or compliance with, any condition or provision of this Agreement to be performed by any other party hereto may be deemed a waiver of similar or dissimilar provisions or conditions at the same time or at any prior or subsequent time.

27.Amendment.  This Agreement may be modified or amended only if such modification or amendment is agreed to in writing and signed by duly authorized representatives of the parties hereto, which writing expressly states the intent of the parties to modify this Agreement.

28.Counterparts.  This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original as against any party that has signed it, but all of which together will constitute one and the same instrument.

29.Assignment.  This Agreement inures to the benefit of and is binding upon the Company and its successors and assigns, but the Employee’s rights under this Agreement are not assignable, except to his estate.

30.Notice.  All notices, requests, demands, claims and other communications hereunder shall be in writing and shall be deemed to have been duly given (a) if personally delivered; (b) if sent by email; or (c) if mailed by overnight or by first class, certified or registered mail, postage prepaid, return receipt requested, and properly addressed as follows: 

	
 
	
If to the Employee:
	
Shalini Sharp
                                               

	
 
	

	
                                                   

	
 
	

	
Email:                                         

 

	
 
	
If to the Company:
	
Ultragenyx Pharmaceutical Inc.

Attn:  General Counsel   
60 Leveroni Court

Novato, CA 94949
Email: kparschauer@ultragenyx.com

                                                        12

 

 

Such addresses may be changed, from time to time, by means of a notice given in the manner provided above.  Notice will conclusively be deemed to have been given when personally delivered (including, but not limited to, by messenger or courier); or if given by mail, on the third day after being sent by first class, certified or registered mail; or if given by Federal Express or other similar overnight service, on the date of delivery; or if given by email during normal business hours on a business day, when confirmation of transmission is indicated by the sender’s machine; or if given by email at any time other than during normal business hours on a business day, the first business day following when confirmation of transmission is indicated by the sender’s machine.  Notices, requests, demands and other communications delivered to legal counsel of any party hereto, whether or not such counsel shall consist of in-house or outside counsel, shall not constitute duly given notice to any party hereto.

                                                        13

 

EACH OF THE PARTIES ACKNOWLEDGES THAT SHE/IT HAS READ THIS AGREEMENT, UNDERSTANDS IT AND IS VOLUNTARILY ENTERING INTO IT, AND THAT IT INCLUDES A WAIVER OF THE RIGHT TO A TRIAL BY JURY, AND, WITH RESPECT TO THE EMPLOYEE,  HE UNDERSTANDS THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the dates indicated below.

		
	
“Employee”
	
 

Shalini Sharp

	
 
	
Dated:                                 , 20__

 

		
	
“Company”
	
ULTRAGENYX PHARMACEUTICAL INC.

	
 
	
By: 

	
 
	
Name:  ________________

	
 
	
Title: __________________  

	
 
	
Dated:                                 , 20__

 

 

 

 

 

 

 

 

 

 

 

 

                                                        14EX-4.1

 Exhibit 4.1 
  

 
  

STOCKHOLDERS’ AGREEMENT 
 BY
AND AMONG 
 ALBERTSONS COMPANIES, INC. 

AND 
 HOLDERS OF STOCK OF
ALBERTSONS COMPANIES, INC. SIGNATORY HERETO 
 Dated as
of                 , 2020 
  

 
  

 TABLE OF CONTENTS 

 
  

							
	 	  	 	  	Page	 
	ARTICLE I DEFINITIONS	  	 	1	 
			
	 Section 1.01.
	  	Defined Terms	  	 	1	 
	 Section 1.02.
	  	 Other Interpretive Provisions
	  	 	3	 
		
	ARTICLE II CORPORATE GOVERNANCE	  	 	4	 
			
	 Section 2.01.
	  	Board Representation	  	 	4	 
	 Section 2.02.
	  	 Board Committees
	  	 	6	 
	 Section 2.03.
	  	 Voting
	  	 	7	 
	 Section 2.04.
	  	 Controlled Company
	  	 	7	 
		
	ARTICLE III GROUP MATTERS	  	 	8	 
			
	 Section 3.01.
	  	Group Agreement	  	 	8	 
		
	ARTICLE IV MISCELLANEOUS	  	 	9	 
			
	 Section 4.01.
	  	Term	  	 	9	 
	 Section 4.02.
	  	 Injunctive Relief
	  	 	9	 
	 Section 4.03.
	  	 Attorneys’ Fees
	  	 	9	 
	 Section 4.04.
	  	 Notices
	  	 	9	 
	 Section 4.05.
	  	 Publicity and Confidentiality
	  	 	12	 
	 Section 4.06.
	  	 Amendment
	  	 	12	 
	 Section 4.07.
	  	 Successors, Assigns and Transferees
	  	 	12	 
	 Section 4.08.
	  	 Binding Effect
	  	 	12	 
	 Section 4.09.
	  	 Third Party Beneficiaries
	  	 	12	 
	 Section 4.10.
	  	 Governing Law; Jurisdiction
	  	 	12	 
	 Section 4.11.
	  	 Waiver of Jury Trial
	  	 	13	 
	 Section 4.12.
	  	 Severability
	  	 	13	 
	 Section 4.13.
	  	 Counterparts
	  	 	13	 
	 Section 4.14.
	  	 Headings
	  	 	13	 
	 Section 4.15.
	  	 Joinder
	  	 	13	 

  
 i 

 STOCKHOLDERS’ AGREEMENT 

This Stockholders’ Agreement (the “Agreement”) is made, entered into and effective as
of                , 2020, by and between                (together,
“Cerberus”),                
(“Schottenstein”),                 (collectively,
“Klaff”),                 (collectively,
“Lubert-Adler”),                 (collectively, “Kimco”, and each of Cerberus, Schottenstein, Klaff, Lubert-Adler and Kimco, a
“Sponsor” and, collectively, the “ACI Control Group”) and Albertsons Companies, Inc., a Delaware corporation (including any of its successors by merger, acquisition, reorganization, conversion or otherwise) (the
“Company”). 
 WITNESSETH 

WHEREAS, as of the date hereof, each of the members of the ACI Control Group owns securities of the Company; and 

WHEREAS, the parties desire to set forth certain rights of members of the ACI Control Group with respect to the Company. 

NOW, THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements of the parties hereto, and for other good
and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 ARTICLE I

 DEFINITIONS 

Section 1.01. Defined Terms(a) . As used in this Agreement, the following terms shall have the following meanings: 

“ACI Control Group” has the meaning set forth in the preamble. 

“ACI Control Group Approval” shall mean the affirmative vote of a majority of the outstanding shares of Company Shares owned
by the ACI Control Group. 
 “Affiliate” shall mean any Person or entity, directly or indirectly controlling, controlled by
or under common control with such Person or entity, including (i) a general partner, limited partner, or retired partner affiliated with such Person or entity, (ii) a fund, partnership, limited liability company or other entity affiliated
with such Person or entity, (iii) a director, officer, stockholder, partner or member (or retired partner or member) affiliated with such Person or entity, or (iv) or the estate of any such partner or member (or retired partner or member)
affiliated with such Person or entity; provided that neither the Company nor any of its subsidiaries shall be deemed to be an Affiliate of the Holders. 

“Agreement” has the meaning set forth in the preamble. 

“Audit Committee” has the meaning set forth in Section 2.02(a). 

 “Board of Directors” means the board of directors of the Company. 

“Business Day” means any day other than a Saturday, Sunday or a day on which commercial banks located in New York, New York
are required or authorized by law or executive order to be closed. 
 “Company” has the meaning set forth in the preamble.

 “Company Share Equivalent” means securities exercisable or exchangeable for, or convertible, into Company Shares. 

“Company Shares” means the shares of common stock, par value $0.01 per share, of the Company, any Equity Securities of the
Company into which such shares of common stock shall have been changed, or any Equity Securities of the Company resulting from any reclassification, recapitalization, reorganization, merger, consolidation, conversion, stock or other equity split or
dividend or similar transactions with respect to such shares of common stock or such other Equity Securities. 
 “Compensation
Committee” has the meaning set forth in Section 2.02(a). 
 “Director Requirements” means with respect to an
individual, that such individual shall not be prohibited by law from service and complies with all applicable corporate governance policies and guidelines of the Company and the Board of Directors and subject to any employment agreement or other
agreement with an employee of the Company or any of its subsidiaries or controlled Affiliates, and all applicable legal, regulatory and stock exchange requirements (other than any requirements under Section 303A of the New York Stock Exchange
Listed Company Manual regarding director independence). 
 “Equity Securities” means, as applicable, (i) any capital
stock, membership interests or other equity interest of any Person; (ii) any securities directly or indirectly convertible into or exchangeable for any capital stock, membership interests or other equity interest of any Person; or
(iii) any rights or options directly or indirectly to subscribe for or to purchase any capital stock, membership interests or other equity interest of any Person or to subscribe for or to purchase any securities directly or indirectly
convertible into or exchangeable for any capital stock, membership interests or other equity interest of any Person. 
 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and any successor thereto, and any rules and regulations promulgated thereunder, all as the same shall be in effect from time to time. 

“Governmental Entity” means any federal, state, local or foreign governmental, administrative, judicial or regulatory agency,
commission, court, body, entity or authority. 
 “Holder” means any holder of Company Shares that is a party hereto and/or
any Permitted Assignee that succeeds to rights hereunder pursuant to Section 4.08. 

  
 2 

 “Law” means foreign or domestic law, statute, code, ordinance, rule,
regulation, order, judgment, writ, stipulation, award, injunction, decree or arbitration award or finding of any Governmental Entity. 

“Nominating Committee” has the meaning set forth in Section 2.02(a). 

“Observer” has the meaning set forth in Section 2.01(h). 

“Permitted Assignee” has the meaning set forth in Section 4.08. 

“Person” means any individual, partnership, corporation, limited liability company, unincorporated organization, trust or
joint venture, or a governmental agency or political subdivision thereof or any other entity. 
 “Representatives” means,
with respect to any Person, any of such Person’s officers, directors, employees, agents, attorneys, accountants, actuaries, consultants, equity financing partners or financial advisors or other Person associated with, or acting on behalf of,
such Person. 
 “Rule 144” means Rule 144 (or any successor provisions) under the Securities Act. 

“SEC” means the Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended, and any successor thereto, and any rules and regulations
promulgated thereunder, all as the same shall be in effect from time to time. 
 “Sponsor” has the meaning set forth in the
preamble. 
 “Voting Stock” of any Person as of any date means the capital stock of such Person that is at the time
entitled to vote in the election of the board of directors of such Person. 
 Section 1.02. Other Interpretive Provisions. 

(a) In this Agreement, except as otherwise provided: 

(i) A reference to an Article, Section, Schedule or Exhibit is a reference to an Article or Section of, or Schedule or Exhibit to, this
Agreement, and references to this Agreement include any recital in or Schedule or Exhibit to this Agreement. 
 (ii) The Schedules form an
integral part of and are hereby incorporated by reference into this Agreement. 
 (iii) Headings and the Table of Contents are inserted for
convenience only and shall not affect the construction or interpretation of this Agreement. 
 (iv) Unless the context otherwise requires,
words importing the singular include the plural and vice versa, words importing the masculine include the feminine and vice 

  
 3 

 
versa, and words importing persons include corporations, associations, partnerships, joint ventures and limited liability companies and vice versa. 

(v) Unless the context otherwise requires, the words “hereof” and “herein”, and words of similar meaning refer to this
Agreement as a whole and not to any particular Article, Section or clause. The words “include”, “includes” and “including” shall be deemed to be followed by the words “without limitation.” 

(vi) A reference to any legislation or to any provision of any legislation shall include any amendment, modification or re-enactment thereof and any legislative provision substituted therefor. 
 (vii) All determinations to be
made by any Holder hereunder may be made by such Holder in its sole discretion, and such Holder may determine, in its sole discretion, whether or not to take actions that are permitted, but not required, by this Agreement to be taken by such Holder,
including the giving of consents required hereunder. 
 (b) The parties hereto have participated jointly in the negotiation and drafting of
this Agreement. In the event an ambiguity or question of intention or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any
party by virtue of the authorship of any provisions of this Agreement. 
 ARTICLE II 

CORPORATE GOVERNANCE 

Section 2.01. Board Representation. 

(a) The Company and each member of the ACI Control Group shall take all reasonable measures, if any, within its respective control to cause
the Board of Directors to consist of at least five (5) directors who qualify as “independent” under the applicable rules of the New York Stock Exchange (the “NYSE”) and as such term is defined in Rule 10A-3(b)(1) under the Exchange Act. Independent directors may include one or more nominees nominated pursuant to this Section 2.01. From and after such time as the Company ceases to a “controlled
company” within the meaning of the corporate governance standards of the NYSE and after the expiration of any applicable transition periods under such standards, the majority of the Board of Directors shall be comprised of members who are
“independent” under the applicable rules of the NYSE and as such term is defined in Rule 10A-3(b)(1) under the Exchange Act. At all times the Company shall take all action necessary to cause the
number of directors constituting the Board of Directors (regardless of the number of independent or other directors otherwise required) to be at least such number as shall be necessary to provide for the designation of one or more directors by each
Sponsor entitled pursuant to this Section 2.01 to designate to the Board of Directors one or more directors. 
 (b) The Company and
each member of the ACI Control Group shall take all reasonable measures, if any, within its respective control, to cause the Chief Executive Officer of the Company to be nominated and supported by the Company for election as a director. 

  
 4 

 (c) For so long as Cerberus has, in the aggregate, beneficial ownership of (i) at least
20% of the aggregate number of Company Shares then outstanding, Cerberus shall be entitled to designate to the Board of Directors four (4) directors; (ii) less than 20% but at least 10% of the aggregate number of Company Shares then
outstanding, Cerberus shall be entitled to designate to the Board of Directors two (2) directors; and (iii) less than 10% but at least 5% of the aggregate number of Company Shares then outstanding, Cerberus shall be entitled to designate
to the Board of Directors one (1) director. 
 (d) For so long as Schottenstein has, in the aggregate, beneficial ownership of at least
5% of the aggregate number of Company Shares then outstanding, Schottenstein shall be entitled to designate to the Board of Directors one (1) director. 

(e) For so long as Klaff has, in the aggregate, beneficial ownership of at least 5% of the aggregate number of Company Shares then
outstanding, Klaff shall be entitled to designate to the Board of Directors one (1) director. 
 (f) For so long as a Sponsor is
entitled to designate one or more directors to the Board of Directors pursuant to this Section 2.01, the Company agrees it shall take all action reasonably available to it to cause such individual(s) who satisfy the Director Requirements (or
any replacement designated by such Sponsor) to be included in the slate of nominees recommended by the Board of Directors to the Company’s stockholders for election as directors at each annual meeting of the stockholders of the Company (and/or
in connection with any special meeting of stockholders or election by written consent) and the Company shall use the same efforts to cause the election of such nominee(s) as it uses to cause other nominees recommended by the Board of Directors to be
elected, including soliciting proxies in favor of the election of such nominee(s). 
 (g) If the number of directors that a Sponsor is
entitled to designate to the Board of Directors is reduced pursuant to the terms of this Section 2.01, then such Sponsor shall promptly cause a number of directors equal to such reduction to resign from service on the Board of Directors,
including all committees thereof. Each Sponsor shall cause any director designated to the Board of Directors by it to resign from service on any committee of the Board of Directors if, as a result of such director’s service on such committee,
such committee does not satisfy the requirements of applicable law or the NYSE rules for service on such committee. 
 (h) In the event that
a vacancy is created at any time by the death, disability, retirement, resignation or removal (with or without cause) of a director designated by a Sponsor to the Board of Directors pursuant to this Section 2.01, or in the event of the failure
of any such nominee of a Sponsor to be elected, the Sponsor who designated such director shall have the right to designate a replacement who satisfies the Director Requirements to fill such vacancy (but only if the Sponsor would be then entitled to
designate such director pursuant to the foregoing provisions of this Section 2.01). The Company shall take all action reasonably available to it to cause such vacancy to be filled by the replacement so designated, and, to the extent permitted
under the Certificate of Incorporation and Bylaws of the Company then in effect, to cause the Board of Directors to promptly elect such designee to the Board of Directors. Any other vacant director position(s) or newly created directorship(s) shall
be filled by the Board of Directors, upon the recommendation of the Nominating Committee. 

  
 5 

 (i) For so long as such Sponsor has, in the aggregate, beneficial ownership of at least 5%
of the aggregate number of Company Shares then outstanding, each of Cerberus, Kimco and Lubert-Adler shall have the right to designate one (1) observer to the Board of Directors (each such observer, an “Observer”). A Sponsor
shall have the right to designate a replacement for any Observer previously designated by such Sponsor at any time and from time to time for so long as such Sponsor has a right to designate an Observer. Robert G. Miller shall also have the right to
be an Observer. 
 (j) An Observer may attend any meeting of the Board of Directors, provided, that no Observer shall have the right
to vote or otherwise participate in the Board of Directors meeting in any way other than to observe any applicable meeting of the Board of Directors. Observers shall be provided advance notice of each meeting of the Board of Directors in the same
manner and at the same time as the other members of the Board of Directors and shall be given copies of all documents, materials and other information as and when given to other members of the Board of Directors, provided that the Observer shall
have executed a non-disclosure and confidentiality agreement and such other acknowledgments and agreements reasonably satisfactory to the Board of Directors. Notwithstanding the foregoing, the Observer shall
be excluded from attending any meeting of the Board of Directors or receiving any materials to the extent necessary to preserve attorney-client privilege, to safeguard highly proprietary or classified information, in the case of any conflict of
interest involving such Observer or as otherwise deemed necessary or advisable by the Board of Directors. The Board of Directors or any committee thereof shall have the right to exclude an Observer from any meeting or portion thereof in the sole
discretion of a majority of the members in attendance at such meeting. Each Observer shall be a natural person. The Company shall reimburse each Observer for his or her reasonable
out-of-pocket costs incurred to attend meetings of the Board of Directors. The Company agrees that each Observer shall be entitled to the benefit of the indemnification
and advancement of expenses provided by, or granted pursuant to, the Bylaws of the Company as if such Observer was a director of the Company. 

Section 2.02. Board Committees. 

(a) The Company shall establish and maintain an audit committee of the Board of Directors (the “Audit Committee”), a
compensation committee of the Board of Directors (the “Compensation Committee”), a nominating and corporate governance committee of the Board of Directors (the “Nominating Committee”), and such other Board of
Directors committees as the Board of Directors deems appropriate from time to time or as may be required by applicable law or the NYSE rules. The committees shall have such duties and responsibilities as are customary for such committees, subject to
the provisions of this Agreement and committee charters adopted by the Board of Directors or the committees. 
 (b) Notwithstanding the
foregoing, the Board of Directors (upon the recommendation of the Nominating Committee) shall, only to the extent necessary to comply with applicable law or the NYSE rules, modify the composition of any such committee. If any vacant director
position on any committee of the Board of Directors results from a Sponsor no longer being entitled to designate at least one (1) director to the Board of Directors or declining to have one (1) of its director designees serve on such
committee, then such vacant position shall be filled by the Board of Directors. 

  
 6 

 Section 2.03. Voting. 

(a) Each member of the ACI Control Group and their respective Permitted Assignees agrees, with respect to all of such Person’s Company
Shares from time to time held by such member to vote such Person’s Company Shares for the directors designated to the Board of Directors in Section 2.01. Each member of the ACI Control Group and each of their respective Permitted
Assignees, shall take all other necessary or desirable actions within such Person’s control (including, without limitation, attending meetings of stockholders in person or by proxy for purposes of obtaining a quorum and execution of written
consents in lieu of meetings) to effect the voting of such Person’s Company Shares in accordance with this provision. 
 (b) To secure
each member of the ACI Control Group’s obligations to vote their respective Company Shares in accordance with Section 2.03(a) of this Agreement, each such Person hereby appoints an officer of the Company as such Person’s true and
lawful proxy and attorney, with the power to act alone and with full power of substitution, to vote all of such Person’s Company Shares as set forth in this Agreement and to execute all appropriate instruments consistent with this Agreement on
behalf of such Person if, and only if, such Person fails to vote all of such Person’s Company Shares or execute such other instruments in accordance with the provisions of this Agreement within five days of the Company’s written request
for such Person’s written consent or signature. The proxy and power granted by each Person pursuant to this Section 2.03(b) are coupled with an interest and are given to secure the performance of such Person’s duties under this
Agreement. Each such member of the ACI Control Group agrees to execute an irrevocable proxy in favor of the designated individual as and when identified, if requested by the Company. Each such proxy and power will be irrevocable for the term hereof.
The proxy and power, so long as any such Person is an individual, will survive the death, incompetency and disability of such party or any other individual holder of any Person’s Company Shares, as the case may be, and, so long as such Person
is an entity, will survive the merger or reorganization of such party or any other entity holding any of a Person’s Company Shares. 

Section 2.04. Controlled Company. 

(a) The Company and the members of the ACI Control Group agree that, by virtue of the combined Company Shares owned by the members of the ACI
Control Group as of the date of this Agreement, the Company qualifies as of the date of this Agreement as a “controlled company” within the meaning of the corporate governance standards of the NYSE. 

(b) For so long as the Company qualifies as a “controlled company” for the purposes of the applicable NYSE rules, the Company shall
elect to be a “controlled company” for purposes of the NYSE rules. If the Company ceases to qualify as a “controlled company” for purposes of the NYSE rules, the Company and members of the ACI Control Group shall take whatever
action may be reasonably necessary in relation to such party, if any, to cause the Company to comply with the applicable NYSE rules as then in effect within the timeframe for compliance available under such rules, including any applicable transition
periods. Notwithstanding the foregoing, upon the mutual election of the Board of Directors and the ACI Control Group, the Company shall elect not to be a “controlled company” for purposes of the NYSE rules and, if so elected, the Company
and the ACI Control Group will take all actions 

  
 7 

 
reasonably necessary in relation to such party, if any, to cause the Company to comply with the NYSE rules as then in effect within the timeframe for compliance available under such rules,
including any applicable transition periods. 
 ARTICLE III 

GROUP MATTERS 

Section 3.01. Group Agreement. 

(a) Each of the members of the ACI Control Group agrees to form a group for the purpose of working together to enhance stockholder value at
the Company. 
 (b) To the extent required by applicable law, in accordance with Rule
13d-1(k)(1)(iii) under the Exchange Act, each member of the ACI Control Group agrees to the joint filing on behalf of each of them of statements on Schedule 13D or Schedule 13G, and any amendments thereto,
with respect to the Company Shares. Each member of the ACI Control Group shall be responsible for the accuracy and completeness of such member’s own disclosure therein, and is not responsible for the accuracy and completeness of the information
concerning the other members, unless such member knows or has reason to know that such information is inaccurate. 
 (c) Each member of the
ACI Control Group shall, no later than 24 hours after each such transaction, provide written notice to Cerberus and Schulte Roth & Zabel LLP of (i) any of their purchases or sales of securities of the Company, or (ii) any
securities of the Company over which they acquire or dispose of beneficial ownership. Cerberus shall also use its reasonable best efforts to notify the other members of the ACI Control Group of any significant purchases or sales of securities on its
behalf and will in any case provide periodic information on sales and purchases upon reasonable request by the other members of the ACI Control Group. 

(d) Each member of the ACI Control Group agrees that, to the extent any SEC filing, press release or public communication proposed to be made
or issued by such member of the ACI Control Group references another member of the ACI Control Group, it shall provide a copy of such material to such referenced member of the ACI Control Group in advance of such filing, disclosure or communication
and consider in good faith any reasonable comments to such material prior to filing or making public. The parties hereto hereby agree to work in good faith to resolve any disagreement that may arise between or among any of the members of the ACI
Control Group concerning decisions to be made, actions to be taken or statements to be made in connection with the ACI Control Group’s activities. 

(e) The ACI Control Group shall be limited to carrying on the business of the group in accordance with the terms of this Agreement. Such
relationship shall be construed and deemed to be for the sole and limited purpose of carrying on such business as described herein. Nothing herein shall be construed to authorize any member of the ACI Control Group to act as an agent for any other
member of the ACI Control Group, or to create a joint venture or partnership. 

  
 8 

 ARTICLE IV 

MISCELLANEOUS 

Section 4.01. Term. This Agreement shall terminate with respect to a Sponsor (and, for purposes of this Agreement, such
Sponsor’s status as a member of the ACI Control Group) when such Sponsor ceases to own 5% of the aggregate number of Company Shares then outstanding. This Agreement shall expire when no member of the ACI Control Group has a right to designate a
director to the Board of Directors pursuant to Section 2.01. 
 Section 4.02. Injunctive Relief. It is hereby agreed and
acknowledged that it will be impossible to measure in money the damage that would be suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved Person will be
irreparably damaged and will not have an adequate remedy at law. Any such Person shall, therefore, be entitled (in addition to any other remedy to which it may be entitled in law or in equity) to injunctive relief, including specific performance, to
enforce such obligations, and if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law. 

Section 4.03. Attorneys’ Fees. In any action or proceeding brought to enforce any provision of this Agreement
or where any provision hereof is validly asserted as a defense, the successful party shall, to the extent permitted by applicable law, be entitled to recover reasonable attorneys’ fees in addition to any other available remedy. 

Section 4.04. Notices. Unless otherwise specified herein, all notices, consents, approvals, reports, designations, requests,
waivers, elections and other communications authorized or required to be given pursuant to this Agreement shall be in writing and shall be deemed to have been given (a) when personally delivered, (b) the day following the day (except if
not a Business Day then the next Business Day) on which the same has been delivered prepaid to a reputable national overnight air courier service, (c) when transmitted via email (including via attached pdf document) to the applicable email
address set forth below, if the sender on the same day sends a confirming copy of such notice by a recognized overnight delivery service (charges prepaid) or (d) the third Business Day following the day on which the same is sent by certified or
registered mail, postage prepaid, in each case to the respective parties, as applicable, at the applicable address, facsimile number or email address set forth below (or such other address, facsimile number or email address as such Holder may
specify by notice to the Company in accordance with this Section 4.04), and the Company, which notices shall be addressed: 
 If to the
Company, to: 
 Albertsons Companies, Inc. 

250 Parkcenter Blvd. 
 Boise, ID
83706 
 Attention: Robert A. Gordon, Esq. 

Email:       Robert.gordon@albertsons.com 

  
 9 

 with copies (which shall not constitute notice) to: 

Schulte Roth & Zabel LLP 

919 Third Avenue 
 New York, New
York 10022 
 Attention: Stuart D. Freedman, Esq. 

Antonio L. Diaz-Albertini, Esq. 

Email: Stuart.Freedman@srz.com 

     Antonio.Diaz-Albertini@srz.com 

If to Cerberus, to: 
 c/o Cerberus
Capital Management, L.P. 
 875 Third Avenue, 11th Floor 

New York, NY 10022 
 Attention:
Lenard Tessler 
 Alex Benjamin, Esq. 

Email: LTessler@cerberus.com 

    Albenjamin@cerberus.com 

with copies (which shall not constitute notice) to: 

Schulte Roth & Zabel LLP 

919 Third Avenue 
 New York, New
York 10022 
 Attention: Stuart D. Freedman, Esq. 

       Antonio L. Diaz-Albertini, Esq. 

Email: Stuart.Freedman@srz.com 

  Antonio.Diaz-Albertini@srz.com 

If to Schottenstein, to: 
 Jubilee
Limited Partnership 
 4300 E. Fifth Ave. 

Columbus, OH 43219 
 Attention:
Ben Kraner 
        Tod H. Friedman, Esq. 

Email: ben.kraner@spgroup.com 

  tod.friedman@spgroup.com 

If to Klaff, to: 
 Klaff Realty,
L.P. 
 35 E. Wacker Drive 

Suite 2900 
 Chicago, IL 60601

  
 10 

 
Attention: Hersch M. Klaff 
 Email: hklaff@klaff.com 

with a copy (which shall not constitute notice) to: 

Fox, Swibel, Levin & Carroll, LLP 

200 W. Madison Street, Suite 3000 

Chicago, IL 60603 
 Attention:
Laurie A. Levin 
 Email: LLevin@foxswibel.com 

If to Lubert-Adler, to: 

Lubert-Adler Partners 
 The FMC
Tower 
 2929 Walnut Street, Suite 1530 

Philadelphia, PA 19104 

Attention: Dean Adler 

   R. Eric Emrich 

Email: dadler@lubertadler.com 

eemrich@lubertadler.com 
 with a
copy (which shall not constitute notice) to: 
 Kirkland & Ellis LLP 

300 North LaSalle 
 Chicago, IL
60654 
 Attention: Richard J. Campbell 

Email: rcampbell@kirkland.com 
 If
to Kimco, to: 
 c/o Kimco Realty Corporation 

3333 New Hyde Park Road, Suite 100 

New Hyde Park, NY 11042 

Attention: Raymond Edwards 

   Bruce Rubenstein 

Email: Redwards@kimcorealty.com 

BRubenstein@kimcorealty.com 

with a copy (which shall not constitute notice) to: 

Fried, Frank, Harris, Shriver & Jacobson LLP 

One New York Plaza 
 New York, New
York 10004 
 Attention: Philip Richter 

  
 11 

 Steven G. Scheinfeld, Esq. 

Email: Philip.richter@friedfrank.com 

Section 4.05. Publicity and Confidentiality. Each of the parties hereto shall keep confidential this Agreement and the
transactions contemplated hereby, and any nonpublic information received pursuant hereto, and shall not disclose, issue any press release or otherwise make any public statement relating hereto or thereto without the prior written consent of the
Company and the ACI Control Group, unless so required by applicable law or any governmental authority; provided that no such written consent shall be required (and each party shall be free to release such information) for disclosures
(a) to each party’s partners, members, advisors, employees, agents, accountants, trustee, attorneys, Affiliates and investment vehicles managed or advised by such party or the partners, members, advisors, employees, agents, accountants,
trustee or attorneys of such Affiliates or managed or advised investment vehicles, in each case so long as such Persons agree to keep such information confidential or (b) to the extent required by law, rule or regulation. 

Section 4.06. Amendment. The terms and provisions of this Agreement may only be amended, modified, waived or terminated at any
time and from time to time by a writing executed by the Company and ACI Control Group Approval; provided, that, any amendment, modification or waiver that would affect the rights, benefits or obligations of any Holder shall require the
written consent of such Holder only if any of the following is applicable: (i) such amendment, modification, waiver or termination would materially and adversely affect such rights, benefits or obligations of such Holder and (ii) such
amendment, modification, waiver or termination would affect such Holder in a materially worse manner than the manner in which such amendment or waiver affects the other Holders. 

Section 4.07. Successors, Assigns and Transferees 

The rights and obligations of each party hereto may not be assigned, in whole or in part, without the written consent of the Company and ACI
Control Group Approval. 
 Section 4.08. Binding Effect. Except as otherwise provided in this Agreement, the terms and
provisions of this Agreement shall be binding on and inure to the benefit of each of the parties hereto and their respective successors. 

Section 4.09. Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended or shall be construed to
confer upon any Person not a party hereto any right, remedy or claim under or by virtue of this Agreement. 
 Section 4.10.
Governing Law; Jurisdiction. THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF. ANY ACTION OR PROCEEDING AGAINST THE PARTIES RELATING
IN ANY WAY TO THIS AGREEMENT MAY BE BROUGHT AND ENFORCED EXCLUSIVELY IN THE COURTS OF THE STATE OF NEW YORK OR (TO THE EXTENT SUBJECT MATTER JURISDICTION EXISTS THEREFOR) THE U.S. DISTRICT COURT 

  
 12 

 
FOR THE SOUTHERN DISTRICT OF NEW YORK, IN EACH CASE SITTING IN THE BOROUGH OF MANHATTAN, AND THE PARTIES IRREVOCABLY SUBMIT TO THE JURISDICTION OF BOTH SUCH COURTS IN RESPECT OF ANY SUCH ACTION
OR PROCEEDING. 
 Section 4.11. Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED
BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES HEREBY
(A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT
IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 4.12. 

Section 4.12. Severability. If any provision of this Agreement shall be held to be invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 4.13. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original,
and all of which shall constitute one and the same agreement. 
 Section 4.14. Headings. The heading references herein and in
the table of contents hereto are for convenience purposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 

Section 4.15. Joinder. Any Person may, with ACI Control Group Approval, be admitted as a party to this Agreement upon its
execution and delivery of a joinder agreement, in form and substance acceptable to the ACI Control Group, agreeing to be bound by the terms and conditions of this Agreement as if such Person were a party hereto (together with any other documents the
ACI Control Group reasonably determines are necessary to make such Person a party hereto), whereupon such Person will be treated as a Holder for all purposes of this Agreement. 

[Remainder of Page Intentionally Blank] 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

			
	ALBERTSONS COMPANIES, INC.
		
	By:	 	 
		 	Name:
		 	Title:

 
			
	HOLDERS:
	
	CERBERUS:
	
	[________]

 
			
		
	By:	 	 
	Name:	 	
	Title:	 	

  
 15 

 
			
	 SCHOTTENSTEIN:

	
	 [________]

			
		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	

 
			
	 KLAFF:

	
	 [________]

			
		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	

 
			
	 LUBERT-ADLER:

	
	 [________]

			
		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	

 
			
	 KIMCO:

	
	 [________]

			
		
	 By:
	 	 
	 Name:
	 	
	 Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]